Anaptys Announces $100 Million Stock Repurchase Plan - AnaptysBio (NASDAQ:ANAB)

Core Viewpoint - AnaptysBio, Inc. has authorized an amended Stock Repurchase Plan allowing for the repurchase of up to $100 million of its common stock, in addition to the remaining $6.4 million from a previous plan [1][2]. Group 1: Stock Repurchase Plan - The amended Stock Repurchase Plan allows AnaptysBio to repurchase up to $100 million of its outstanding common stock, with $6.4 million remaining from the previous $75 million plan [1]. - As of November 20, 2025, AnaptysBio has repurchased a total of 3,443,188 shares, representing 11.2% of shares outstanding before the initiation of the repurchase plan [1]. - The repurchase may occur through open market transactions or other means, with the plan set to expire on March 31, 2026, and can be suspended or discontinued at any time [3]. Group 2: Financial Position - AnaptysBio anticipates ending 2025 with approximately $300 million in cash, cash equivalents, and investments, which includes a one-time $75 million commercial sales milestone expected in Q4 2025 from GSK [2]. Group 3: Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, with a pipeline that includes several candidates in various stages of clinical trials [4]. - The company has out-licensed therapeutic antibodies, including a PD-1 antagonist to GSK and an IL-36R antagonist to Vanda Pharmaceuticals [4]. - AnaptysBio plans to separate its biopharma operations from its royalty assets by the end of 2026, allowing investors to align their investment strategies with each entity's objectives [5].